Wegovy Rash and Itching: Injection-Site Reactions and Hypersensitivity (Semaglutide 2.4 mg)

“Wegovy rash” is the search-box phrase people reach for after they notice a skin change while taking Wegovy — semaglutide dosed at 2.4 mg once weekly for weight loss, the obesity-strength version of the same molecule sold as Ozempic at lower doses for diabetes. Because Wegovy titrates up to a higher dose than Ozempic, some people find injection-site reactions a little more noticeable during the ramp-up, and that is exactly the kind of thing that drives the search. The honest answer is that “Wegovy rash” is really three different things, and the entire point of this guide is to keep them apart. The common one is a small patch of redness, itching, or a firm bump right where the pen injects — an injection-site reaction, mild and short-lived. The less common one is a more widespread rash or generalized itching. The rare but serious one is a true hypersensitivity reaction: fast-spreading hives, swelling of the lips, tongue, or throat (angioedema), trouble breathing (anaphylaxis), or a delayed drug-rash syndrome with fever. The first is expected and manageable; the third is a stop-the-pen-and-get-help emergency. This article is Wegovy-specific — what the obesity trials actually reported at 2.4 mg, what each reaction looks like, how long it lasts, and the red flags that mean call for help now.

Why the Wegovy dose matters for skin reactions

Wegovy and Ozempic are the same active drug — semaglutide — delivered by a once-weekly subcutaneous pen. The difference is the dose and the indication: Ozempic is titrated for type 2 diabetes (typically up to 1 or 2 mg), while Wegovy is titrated over roughly 16 to 20 weeks to a 2.4 mg maintenance dose for chronic weight management. More injected drug, and a longer step-up schedule, is the practical reason some people perceive injection-site reactions as more frequent or more noticeable on Wegovy — particularly while the dose is climbing. The reaction types, though, are the same as for any GLP-1, and they sort along the same gradient from common-and-mild to rare-and-serious that the dermatology literature describes for this drug class (Ho 2026^[4]). We cover the lower-dose, diabetes-framed version of this topic in our companion piece on the Ozempic rash; this guide stays on the 2.4 mg obesity dose.

Injection-site reactions on Wegovy — the common, usually mild one

By far the most frequent skin complaint on Wegovy is a local injection-site reaction: redness, itching, mild tenderness, or a small raised welt or firm bump exactly where the pen delivered the dose. It typically shows up within hours to a day or two of the weekly injection and fades over a few days. Crucially, the obesity trials that established Wegovy at 2.4 mg looked specifically for these. In STEP 1 — the pivotal 68-week trial of semaglutide 2.4 mg in adults with overweight or obesity — injection-site reactions were reported as a recognized but generally mild adverse event, more common than with placebo yet rarely a reason anyone stopped the drug (Wilding 2021^[1]). The longer-term picture is reassuring on the same point: in STEP 5, which followed adults on semaglutide 2.4 mg for a full two years, the safety profile stayed consistent with the shorter trials, with no signal that injection-site or skin reactions worsened or accumulated over time (Garvey 2022^[2]). For comparison, lower-dose semaglutide in the diabetes cardiovascular trial SUSTAIN-6 produced injection-site reactions that were uncommon and predominantly mild (Marso 2016^[3]) — consistent with the idea that the higher 2.4 mg dose makes these reactions somewhat more noticeable, not categorically different.

What helps a Wegovy injection-site reaction

• Rotate your sites. Don't inject the same spot every week. Alternate among the abdomen (avoiding the area right around the navel), the front of the thighs, and the back of the upper arms. Systematic site rotation is the single best-evidenced way to cut down local reactions and lumps, carried over from injection-technique guidance for other subcutaneous medicines (Frid 2016^[9]). This matters more on Wegovy precisely because you may be injecting a higher dose during titration.
• Check your technique. Let an alcohol swab dry fully before injecting, use the pen's fresh needle, inject into subcutaneous fat (not muscle), and don't rub hard afterward. Letting a refrigerated Wegovy pen come toward room temperature before dosing can reduce sting.
• Soothe it. A cool compress and an over-the-counter antihistamine or low-strength hydrocortisone can ease itching and redness while it settles. Avoid scratching, which can prolong it or break the skin.
• Give firm bumps time. A small nodule under the skin can take longer to disappear than simple redness; keep injecting elsewhere and it usually shrinks over weeks. Mention any bump that is growing, painful, warm, or draining to your prescriber.

Generalized rash and itching on Wegovy — less common

Some people on Wegovy develop itching or a rash away from the pen site — itchy patches, hives (raised, pale, intensely itchy welts that come and go), or diffuse itching without an obvious local cause. This is less common than the local reaction and sits in the middle of the spectrum: usually benign and antihistamine-responsive, but occasionally the first sign of a true drug hypersensitivity, so it deserves a closer look rather than being ignored. Report it to your prescriber, especially if it coincided with a dose increase.

Hives (urticaria) specifically are an itchy, raised, migrating rash driven largely by histamine release. Most acute hives are self-limited and respond to second-generation antihistamines, the first-line treatment in urticaria guidelines (Zuberbier 2022^[5]). If hives persist for weeks or keep recurring, that is a separate clinical picture — our dedicated piece on chronic hives on a GLP-1 covers the workup and where omalizumab (Xolair) fits. The key triage question with any hives on Wegovy is speed and company: hives that spread fast, or come with any swelling of the face or throat or any breathing change, are an emergency, not a nuisance.

Rare but serious — Wegovy hypersensitivity reactions you must not miss

Serious allergic and hypersensitivity reactions to Wegovy are rare, but because they are dangerous they are the reason to know the red flags cold. The Wegovy prescribing information lists serious hypersensitivity reactions — including anaphylaxis and angioedema — as a known though uncommon risk and a reason to stop the drug. There are three patterns to recognize.

Anaphylaxis and angioedema (minutes to hours)

Anaphylaxis is a rapid, multi-system allergic reaction — typically within minutes to a couple of hours of a dose — that can include widespread hives, swelling, breathing difficulty, throat tightness, vomiting, a drop in blood pressure, dizziness, or collapse. Angioedema is deeper swelling, classically of the lips, tongue, face, or throat, that can compromise the airway. Both are medical emergencies: World Allergy Organization guidance is unambiguous that suspected anaphylaxis is treated with intramuscular epinephrine without delay, alongside emergency evaluation (Cardona 2020^[6]). If this happens on Wegovy, the pen is stopped and not restarted except under specialist allergy guidance.

DRESS and severe delayed drug rashes (days to weeks)

A different and slower danger is a severe delayed drug reaction. The one to know by name is DRESS — Drug Reaction with Eosinophilia and Systemic Symptoms — which typically appears two to eight weeks after starting a culprit drug and combines a widespread rash with fever, facial swelling, swollen lymph nodes, and internal-organ involvement (often the liver), with a high eosinophil count on bloodwork (Cacoub 2011^[7]). It is rare, but it is an emergency: it requires stopping the drug immediately and hospital-level care, because organ involvement can be life-threatening. On a titrating drug like Wegovy, a rash that arrives with fever and facial swelling a few weeks after a dose step-up is a fundamentally different signal from a small itchy welt at the pen site on dose-day, and must be treated as serious.

Compounded semaglutide and excipient reactions

One nuance applies to compounded semaglutide rather than the branded Wegovy pen: a skin reaction may be a response to what else is in the vial, not just the active peptide. Compounded products can use different salt forms, preservatives, buffers, and excipients than the FDA-approved Wegovy pen, and a preservative or excipient is a plausible trigger for a local or generalized skin reaction. Pharmacovigilance analysis of compounded GLP-1 receptor agonists using the FDA adverse-event reporting system has flagged that the safety profile of compounded products is less well characterized and warrants caution (McCall 2026^[8]). Practically: if you react on a compounded semaglutide, tell your prescriber and pharmacy, ask exactly what the formulation contains, and recognize that switching formulation or manufacturer — including moving to the branded Wegovy pen — changes the excipient exposure. None of this means a reaction is automatically the compounder's fault, but it is a variable worth naming when you and your clinician work out the cause.

How long does a Wegovy rash last?

• Injection-site reactions: usually a few days. Redness and itch typically peak within a day of the weekly dose and fade over several days. A firm bump can linger for weeks before resolving and occasionally needs a clinician's help. These may feel slightly more noticeable in the weeks you titrate Wegovy upward, then settle once you reach a steady maintenance dose (Wilding 2021^[1]).
• Acute hives / generalized rash: often days, sometimes resolving between weekly doses; antihistamines speed relief. Hives lasting six weeks or more are considered chronic and need a different workup (Zuberbier 2022^[5]).
• Serious hypersensitivity: this isn't about waiting it out. Anaphylaxis and angioedema evolve over minutes to hours and need emergency treatment; DRESS evolves over days to weeks and needs hospital care — in both, the drug is stopped, not timed (Cardona 2020^[6]; Cacoub 2011^[7]).

About "Wegovy rash pictures"

“Wegovy rash pictures” is one of the most common searches on this topic, and it is worth being honest about its limits. Photos can help you recognize a typical mild injection-site reaction — a coin-sized patch of redness or a small welt at the pen site — but they are a poor and sometimes dangerous tool for diagnosing the serious reactions, which are defined by what they do (spread fast, swell the airway, add fever and organ symptoms) more than by a single still image. A photo cannot tell you whether your lip swelling is progressing or whether your fever-plus-rash is DRESS. Use images to calm reasonable worry about a small local bump; use the red-flag checklist, not a photo gallery, to decide whether something is an emergency. When in doubt, send a photo to your own clinician along with the timeline and your current Wegovy dose.

Bottom line

• “Wegovy rash” covers three different things — a common mild injection-site reaction, a less common generalized rash or itching, and a rare but serious hypersensitivity reaction. Keeping them separate is the whole game.
• Because Wegovy is the 2.4 mg obesity dose of semaglutide titrated over months, injection-site reactions can feel more noticeable during the ramp-up than on lower-dose Ozempic — but the STEP trials showed them to be generally mild and not a frequent reason to stop, with a stable profile out to two years (Wilding 2021^[1]; Garvey 2022^[2]).
• Generalized rash or hives is less common, often antihistamine-responsive, and worth reporting because it occasionally signals true hypersensitivity (Zuberbier 2022^[5]).
• Serious hypersensitivity — fast-spreading hives, airway swelling/angioedema, anaphylaxis (Cardona 2020^[6]), or delayed rash-plus-fever DRESS (Cacoub 2011^[7]) — is rare but an emergency: stop the pen and seek care.
• With compounded semaglutide, a preservative or excipient can also be the trigger, and the compounded safety profile is less well characterized (McCall 2026^[8]).
• Use “rash pictures” to reassure yourself about a small local bump — but use the red-flag checklist, not a photo, to decide if something is serious.

Related research

• Ozempic rash and itching — the same three-tier skin-reaction map for the lower-dose, diabetes-framed version of semaglutide.
• Chronic hives on a GLP-1 — when itchy welts last six weeks or more, the workup, and where omalizumab fits.
• Wegovy vs. Ozempic — how the same molecule differs by dose, indication, and what the trials showed.
• GLP-1 side-effect questions answered — a plain-language tour of the common and less-common effects of semaglutide and tirzepatide.

Important disclaimer. This article is educational and does not constitute medical advice. Skin reactions vary widely between individuals, and the same symptom can be trivial in one person and serious in another. If you have any red-flag symptom — airway or facial swelling, breathing difficulty, fast-spreading hives, fainting, or a rash with fever — seek emergency care immediately and do not take another Wegovy dose until evaluated. For any persistent or worsening rash, contact your prescriber. Every primary source cited here was verified against the live PubMed E-utilities API on 2026-06-19.